A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
← catalyst calendarNCT07000149 · readout in 163 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
9actual
Sites
3
Countries
Australia, South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-28 | actual | When the study began enrolling |
| Primary completion | 2027-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Clear Cell Renal Cell Carcinoma
Interventions
- Drug: Volrustomig — also filed as MEDI5752
- Drug: Casdatifan — also filed as AB521
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious adverse events (SAEs)
measured Up to Day 90 (+7) post last dose
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed